GLORIA

GEOMAR Library Ocean Research Information Access

You have 0 saved results.
Mark results and click the "Add To Watchlist" link in order to add them to this list.

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Material
Language
Years
  • 1
    In: Future Virology, Informa UK Limited, Vol. 9, No. 12 ( 2014-12), p. 1019-1031
    Type of Medium: Online Resource
    ISSN: 1746-0794 , 1746-0808
    Language: English
    Publisher: Informa UK Limited
    Publication Date: 2014
    detail.hit.zdb_id: 2254606-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: BMC Cancer, Springer Science and Business Media LLC, Vol. 23, No. 1 ( 2023-09-18)
    Abstract: Vietnam and Saudi Arabia have high disease burden of primary hepatocellular carcinoma (HCC). Early detection in asymptomatic patients at risk for HCC is a strategy to improve survival outcomes in HCC management. GALAD score, a serum-based panel, has demonstrated promising clinical utility in HCC management. However, in order to ascertain its potential role in the surveillance of the early detection of HCC, GALAD needs to be validated prospectively for clinical surveillance of HCC (i.e., phase IV biomarker validation study). Thus, we propose to conduct a phase IV biomarker validation study to prospectively survey a cohort of patients with advanced fibrosis or compensated cirrhosis, irrespective of etiologies, using semi-annual abdominal ultrasound and GALAD score for five years. Methods We plan to recruit a cohort of 1,600 patients, male or female, with advanced fibrosis or cirrhosis (i.e., F3 or F4) and MELD ≤ 15, in Vietnam and Saudi Arabia ( n  = 800 each). Individuals with a liver mass ≥ 1 cm in diameter, elevated alpha-fetoprotein (AFP) (≥ 9 ng/mL), and/or elevated GALAD score (≥ -0.63) will be scanned with dynamic contrast-enhanced magnetic resonance imaging (MRI), and a diagnosis of HCC will be made by Liver Imaging Reporting and Data System (LiRADS) assessment (LiRADS-5). Additionally, those who do not exhibit abnormal imaging findings, elevated AFP titer, and/or elevated GALAD score will obtain a dynamic contrast-enhanced MRI annually for five years to assess for HCC. Only MRI nearest to the time of GALAD score measurement, ultrasound and/or AFP evaluation will be included in the diagnostic validation analysis. MRI will be replaced with an abdominal computed tomography scan when MRI results are poor due to patient conditions such as movement etc. Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MRI will not be carried out in study sites in both countries. Bootstrap resampling technique will be used to account for repeated measures to estimate standard errors and confidence intervals. Additionally, we will use the Cox proportional hazards regression model with covariates tailored to the hypothesis under investigation for time-to-HCC data as predicted by time-varying biomarker data. Discussion The present work will evaluate the performance of GALAD score in early detection of liver cancer. Furthermore, by leveraging the prospective cohort, we will establish a biorepository of longitudinally collected biospecimens from patients with advanced fibrosis or cirrhosis to be used as a reference set for future research in early detection of HCC in the two countries. Trial registration Name of the registry: ClinicalTrials.gov Registration date: 22 April 2022 Trial registration number: NCT05342350 URL of trial registry record
    Type of Medium: Online Resource
    ISSN: 1471-2407
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2023
    detail.hit.zdb_id: 2041352-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Stem Cells International, Wiley, Vol. 2016, No. 1 ( 2016-01)
    Abstract: Because of self‐renewal, strong proliferation in vitro , abundant sources for isolation, and a high differentiation capacity, mesenchymal stem cells are suggested to be potentially therapeutic for liver fibrosis/cirrhosis. In this study, we evaluated the treatment effects of mouse bone marrow‐derived mesenchymal stem cells (BM‐MSCs) on mouse liver cirrhosis induced by carbon tetrachloride. Portal and tail vein transplantations were examined to evaluate the effects of different injection routes on the liver cirrhosis model at 21 days after transplantation. BM‐MSCs transplantation reduced aspartate aminotransferase/alanine aminotransferase levels at 21 days after injection. Furthermore, BM‐MSCs induced positive changes in serum bilirubin and albumin and downregulated expression of integrins (600‐ to 7000‐fold), transforming growth factor, and procollagen‐ α 1 compared with the control group. Interestingly, both injection routes ameliorated inflammation and liver cirrhosis scores. All mice in treatment groups had reduced inflammation scores and no cirrhosis. In conclusion, transplantation of BM‐MSCs via tail or portal veins ameliorates liver cirrhosis in mice. Notably, there were no differences in treatment effects between tail and portal vein administrations. In consideration of safety, we suggest transfusion of bone marrow‐derived mesenchymal stem cells via a peripheral vein as a potential method for liver fibrosis treatment.
    Type of Medium: Online Resource
    ISSN: 1687-966X , 1687-9678
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2016
    detail.hit.zdb_id: 2573856-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Bulletin of the Korean Chemical Society, Korean Chemical Society, Vol. 34, No. 1 ( 2013-01-20), p. 263-266
    Type of Medium: Online Resource
    ISSN: 0253-2964
    Language: English
    Publisher: Korean Chemical Society
    Publication Date: 2013
    detail.hit.zdb_id: 774376-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Biomedical Research and Therapy, Biomedical Research and Therapy, Vol. 4, No. 06 ( 2017-06-25), p. 1374-
    Abstract: Background: The application of mesenchymal stem cell (MSC) therapy in liver fibrosis treatment has been increasingly investigated in recent years. MSCs obtained from a variety of sources (e.g. bone marrow, umbilical cord blood and adipose tissue) have been studied and have achieved remarkable results. In this study, we compared the effects of adipose-derived mesenchymal stem cells (AD-MSC) transplantation with bone marrow-derived mesenchymal stem cell (BM-MSC) transplantation in a mouse model of liver fibrosis, induced by carbon tetrachloride (CCl4). Methods: Eight-week old mice were treated with CCl4 for 11 weeks to induce liver fibrosis then 5x105 cells were transplanted into mice via the tail vein. Results: After 21 days of transplantation, the results showed that the stem cell treated groups ameliorated better than the placebo group. MSC treated groups showed reduced AST and ALT levels, down-regulated expression of extracellular matrix (ECM) genes, and improved liver histopathology. Both sources of MSCs (bone marrow and adipose tissue) were effective in the mouse model of liver fibrosis. Conclusion: Our results also indicated that AD-MSC transplantation in mice accelerated liver regeneration better than BM-MSC transplantation.
    Type of Medium: Online Resource
    ISSN: 2198-4093 , 2198-4093
    Language: Unknown
    Publisher: Biomedical Research and Therapy
    Publication Date: 2017
    detail.hit.zdb_id: 2806789-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Biomedical Research and Therapy, Biomedical Research and Therapy, Vol. 4, No. S ( 2017-09-05), p. 157-
    Abstract: Background: Because of their ease of isolation, high proliferation capacity in vitro, as well as their ability to differentiate into liver cells, Adipose-derived stem cell (ADSCs), are considered to be a promised candidate for liver disease treatment, including liver cirrhosis treatment. Recent studies show that hepatocyte growth factor (HGF) can stimulate ADSC to migrate to the injured areas and platelet rich plasma (PRP) can increase the stemness of ADSCs. Method: In this study, we cultured ADSCs in the medium supplemented 20 ng/ml and 10% PRP; then transplanted them into the cirrhosis mouse model. After 11 weeks of CCl4 induction (1ml/kg, three times per week), mice were divided into 3 groups: (1) PBS group which were injected 0.2 ml PBS; (2) ADSC group which were transplanted 5x105 ADSCs non-pretreated with HGF and PRP; (3) ADSC/HGF+PRP group which were transplanted 5x105 ADSCs pretreated with HGF and PRP via the tail vein. We evaluated the effectiveness of the therapeutic at the day 7th and 14th after transplantation. Results: The results show that the transplantation of ADSC pretreated with HGF and PRP after seven days improves the body weight (increase 4.673%); decreases the ALT level (p 〈 0.05), the total leukocyte number (p 〈 0.05) and the expression of Pro-collagen (decrease 4.1 times) as well as α-SMA (decrease 5.1 times), in comparison to the ADSC group. ADSCs pretreated with HGF and PRP also help to improve the liver tissue structure. Conclusion: The therapy using ADSCs pretreated with HGF and PRP is considered to be a promising therapy.
    Type of Medium: Online Resource
    ISSN: 2198-4093 , 2198-4093
    Language: Unknown
    Publisher: Biomedical Research and Therapy
    Publication Date: 2017
    detail.hit.zdb_id: 2806789-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    Online Resource
    Online Resource
    Biomedical Research and Therapy ; 2017
    In:  Biomedical Research and Therapy Vol. 4, No. S ( 2017-09-05), p. 111-
    In: Biomedical Research and Therapy, Biomedical Research and Therapy, Vol. 4, No. S ( 2017-09-05), p. 111-
    Abstract: Background: Up to date, there have been some studies indicating positive effects of stem cells on treating the liver cirrhosis. In this study, we compared the effectiveness of two methods in which mesenchymal stem cells harvested from umbilical cord blood (UCB-MSCs) were transfused either via portal or tail veins to the mouse models of liver cirrhosis.  Methods: Liver cirrhosis was induced by CCl4 (1 ml/kg) on male Swiss mice within 11 weeks, followed by administration of 106 UCB-MSCs via the portal or tail vein. After 21 days, blood samples were collected for measuring transaminase, bilirubin and albumin activities. The expression of fibrosis-associated genes, specifically procollagen – alpha 1 and integrin – beta1, were assessed using qRT-PCR. The histopathology was also evaluated using hematoxylin/eosin, Masson trichrome staining and immunohistochemistry with collagen type 1 and alpha-SMA antibody.  Results: UCB-MSCs transplantation significantly improved post-21 days of treatment in the liver fibrosis mice as compared with placebo group. Notably, UCB-MSCs transferred through portal veins revealed a more positive effect than via tail veins as indicated by the improvement in the biochemical indexes, fibrosis-related genes expression, and liver histopathology.  Conclusion: The UCB-MSCs therapy proved to be a promising method for treating the liver cirrhosis. The method of delivering stem cells through portal vein was more effective than through tail vein
    Type of Medium: Online Resource
    ISSN: 2198-4093 , 2198-4093
    Language: Unknown
    Publisher: Biomedical Research and Therapy
    Publication Date: 2017
    detail.hit.zdb_id: 2806789-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Animal Bioscience, Asian Australasian Association of Animal Production Societies, Vol. 34, No. 5 ( 2021-05-01), p. 867-879
    Abstract: Objective: Fibronectin 3 (FN3) and immunoglobulin like modules (Ig) are usually collocated beside modular cellulase catalytic domains. However, very few researches have investigated the role of these modules. In a previous study, we have sequenced and analyzed bacterial metagenomic DNA in Vietnamese goats' rumen and found that cellulase-producing bacteria and cellulase families were dominant. In this study, the properties of modular cellulases and the role of a FN3 in unique endoglucanase belonging to glycosyl hydorlase (GH) family 5 were determined.Methods: Based on Pfam analysis, the cellulases sequences containing FN3, Ig modules were extracted from 297 complete open reading frames (ORFs). The alkaline, thermostability, tertiary structure of deduced enzymes were predicted by AcalPred, TBI software, Phyre2 and Swiss models. Then, whole and truncated forms of a selected gene were expressed in Escherichia coli and purified by His-tag affinity column for assessment of FN3 ability to enhance enzyme activity, solubility and conformation.Results: From 297 complete ORFs coding for cellulases, 148 sequences containing FN3, Ig were identified. Mostly FN3 appeared in 90.9% beta-glucosidases belonging to glycosyl hydrolase family 3 (GH3) and situated downstream of catalytic domains. The Ig was found upstream of 100% endoglucanase GH9. Rarely FN3 was seen to be situated downstream of X domain and upstream of catalytic domain endoglucanase GH5. Whole enzyme (called XFN3GH5 based on modular structure) and truncate forms FN3, XFN3, FN3GH5, GH5 were cloned in pET22b (+) and pET22SUMO to be expressed in single and fusion forms with a small ubiquitin-related modifier partner (S). The FN3, SFN3 increased GH5 solubility in FN3GH5, SFN3GH5. The SFN3 partly served for GH5 conformation in SFN3GH5, increased modules interaction and enzyme-soluble substrate affinity to enhance SXFN3GH5, SFN3GH5 activities in mixtures. Both SFN3 and SXFN3 did not anchor enzyme on filter paper but exfoliate and separate cellulose chains on filter paper for enzyme hydrolysis.Conclusion: Based on these findings, the presence of FN3 module in certain cellulases was confirmed and it assisted for enzyme conformation and activity in both soluble and insoluble substrate.
    Type of Medium: Online Resource
    ISSN: 2765-0189 , 2765-0235
    Language: English
    Publisher: Asian Australasian Association of Animal Production Societies
    Publication Date: 2021
    detail.hit.zdb_id: 3055169-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Diversity, MDPI AG, Vol. 14, No. 3 ( 2022-03-17), p. 220-
    Abstract: We aimed to investigate the microbial diversity, mine lignocellulose-degrading enzymes/proteins, and analyze the domain structures of the mined enzymes/proteins in humus samples collected from the Cuc Phuong National Park, Vietnam. Using a high-throughput Illumina sequencer, 52 Gbs of microbial DNA were assembled in 2,611,883 contigs, from which 4,104,872 open reading frames (ORFs) were identified. Among the total microbiome analyzed, bacteria occupied 99.69%; the five ubiquitous bacterial phyla included Proteobacteria, Bacteroidetes, Actinobacteria, Firmicutes, and Acidobacteria, which accounted for 92.59%. Proteobacteria (75.68%), the most dominant, was 5.77 folds higher than the second abundant phylum Bacteroidetes (13.11%). Considering the enzymes/proteins involved in lignocellulose degradation, 22,226 ORFs were obtained from the annotation analysis using a KEGG database. The estimated ratio of Proteobacteria/Bacteroidetes was approximately 1:1 for pretreatment and hemicellulases groups and 2.4:1 for cellulases. Furthermore, analysis of domain structures revealed their diversity in lignocellulose-degrading enzymes. CE and PL were two main families in pretreatment; GH1 and GH3-FN3 were the highest domains in the cellulase group, whereas GH2 and GH43 represented the hemicellulase group. These results validate that natural tropical forest soil could be considered as an important source to explore bacteria and novel enzymes/proteins for the degradation of lignocellulose.
    Type of Medium: Online Resource
    ISSN: 1424-2818
    Language: English
    Publisher: MDPI AG
    Publication Date: 2022
    detail.hit.zdb_id: 2518137-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Progress in Stem Cell, Biomedical Research and Therapy, Vol. 4, No. 2 ( 2017-09-10), p. 201-
    Abstract: Introduction: To date, there have been many studies indicating the positive effects of stem cells on treating liver cirrhosis. In this study, we used umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs) for treatment in a mouse model of liver cirrhosis. Specifically, we determined and compared the effectiveness of two methods of MSC injection (tail vein versus portal vein). Methods: Liver cirrhosis in male Swiss mice (of age approximately 11 weeks or under) was induced by administration of carbon tetrachloride (CCl4; 1 ml/kg). One million UCB-MSCs were then transplanted into cirrhotic mice via the portal vein or tail vein. After 21 days, blood samples were collected for measurement of transaminase, bilirubin and albumin. The expression of fibrosis-associated genes, specifically procollagen – alpha 1 and integrin – beta1, were assessed using quantitative RT-PCR. The histopathology of the specimens was also evaluated using hematoxylin/eosin, Masson trichrome staining, and immunohistochemistry using collagen type 1 and alpha-SMA antibodies. Results: After 21 days, cirrhotic mice treated with UCB-MSCs showed recovery of bilirubin index, increase of liver albumin synthesis, inhibition of fibrosis-related gene expression (e.g. procollagen – alpha 1 and integrin – beta1), and remodeling of liver histology. From comparison of the different routes of transplantation, UCB-portal route was significantly more effective than UCB-tail route at reducing aspartate transaminase (AST) activity and bilirubin index (P 〈 0.05), and inhibiting procollagen – alpha 1 and integrin – beta1 expression (P 〈 0.05). UCB-MSCs from both transfusion routes showed accelerated improvement of liver histopathology. Conclusion: Therapeutic strategies using UCB-MSCs have proven to be promising for the treatment of liver cirrhosis. Injection of UCB-MSC via portal vein was more effective than tail vein for cirrhosis treatment.   Peer Review Details Peer review method: Single-Blind (Peer-reviewers: 02) Peer-review policy Plagiarism software screening?: Yes Date of Original Submission: 17 August 2017 Date accepted: 30 August 2017 Peer reviewers approved by: Dr. Lili Hami Editor who approved publication: Dr. Phuc Van Pham  
    Type of Medium: Online Resource
    ISSN: 2199-4633 , 2199-4633
    Language: Unknown
    Publisher: Biomedical Research and Therapy
    Publication Date: 2017
    detail.hit.zdb_id: 2884219-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...